Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements study identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By... https://dereke047bjr1.blogsmine.com/profile